$144,283.94 ownership Payment -- Biogen to Dr. Christine Edwards

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Biogen made a $144.3K ownership payment to Christine Edwards, a Internal Medicine specialist in Dallas, TX. Biogen reported a significant ownership interest payment of $144,283.94 to Christine Edwards, an Internal Medicine physician in Dallas, TX. This payment, categorized as 'Ownership or Investment Interest', occurred on March 27, 2026. The substantial amount suggests a potentially deep financial relationship beyond typical consulting or speaking fees.

Patient Guidance: What This Payment Means for You

If you are a physician receiving ownership interest from a pharmaceutical company, understand the terms and potential implications for your practice and patient care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership interest payments are less common than consulting or speaking fees for Internal Medicine physicians and this amount is considerably higher than average for such arrangements.

Regulatory Context: Sunshine Act Requirements

Physicians must disclose ownership interests in pharmaceutical companies to ensure transparency and avoid potential conflicts of interest under federal regulations.

Related Topics

This payment is related to the following healthcare transparency topics:

• ownership-interest
• biogen
• christine-edwards
• internal-medicine
• dallas-tx
• payment-analysis

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $144.3K payment for?

This was a ownership payment of $144.3K from Biogen to Christine Edwards, categorized as "Ownership or Investment Interest". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Christine Edwards accept pharmaceutical money?

Yes, Christine Edwards received this $144.3K payment from Biogen. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Christine Edwards's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $144.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Internal Medicine?

To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Christine Edwards's relationship with Biogen?

The payment type is 'ownership', indicating a stake in the company rather than a service fee. This $144.3K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Internal Medicine?

The amount is substantial, exceeding typical per-event payments.

What should patients do after learning about this payment?

If you are a physician receiving ownership interest from a pharmaceutical company, understand the terms and potential implications for your practice and patient care.

What else should I know about this ownership payment?

The payment date is in the future (2026), which may indicate a planned or ongoing arrangement.

Related Reports

• View Dr. Christine Edwards's full payment report
• Biogen full spending report
• Browse all Internal Medicine payments
• Browse all payments in Texas
• Search for other payments